Quick Facts: Regitin

• Management of Pheochromocytoma: Supports the control of hypertensive episodes associated with this condition, particularly during surgical preparation and removal.
• Dermal Safety: Used to prevent or provide care for skin tissue injury (necrosis) that may occur following the localized leakage (extravasation) of certain intravenous pressor agents.
• Diagnostic Use: Utilized as a specialized test component for the diagnosis of pheochromocytoma.

---

Regitin is a prescription medication utilized in specific acute and diagnostic medical settings. Its primary approved uses involve the management of catecholamine-induced conditions.

The medication is administered to help stabilize blood pressure during surgical procedures for pheochromocytoma, which is a tumor leading to excessive catecholamine production. It assists in the prevention or control of related hypertensive crises. Furthermore, Regitin has a role in managing complications associated with the administration of pressor agents. It is indicated for the prevention and care of dermal necrosis and sloughing that may follow the unintended local injection or leakage of agents like norepinephrine at the intravenous administration site.

Regitin is also approved for use in a specific pharmacological test to aid in the diagnosis of pheochromocytoma. This diagnostic procedure relies on the medication's intended effect on blood pressure to indicate the presence of the tumor.

Eligibility for Regitin (Phentolamine)

Regitin is restricted to specific patient populations and is absolutely contraindicated in others, as defined by official regulatory labeling.

Contraindicated Populations (Must Not Use)	Age-Related Eligibility
Patients with a history of myocardial infarction (MI).	Adults are the standard population for approved acute and diagnostic uses.
Patients with coronary artery disease (CAD), angina, or coronary insufficiency.	Pediatric use (children) is not established for the injectable form; use is restricted.
Patients with known hypersensitivity to phentolamine.	Older adults may require cautious use due to increased sensitivity.
Patients with a history of cerebrovascular occlusion (stroke) or cerebrovascular spasm.

Pregnancy and Lactation:

Use during pregnancy is restricted and permitted only if the potential benefit justifies the potential risk to the fetus (FDA Pregnancy Category C). For lactation, use is not recommended due to the unknown excretion of the drug into human milk and the potential for serious adverse effects in the nursing infant.

Interactions with other medicines and products

Regitin (Phentolamine mesylate) exhibits documented interaction patterns that are primarily pharmacodynamic in nature, affecting the cardiovascular system, and are supplemented by strict timing requirements for its diagnostic use.

Pharmacodynamic Interactions and Prohibitions

Co-administration with other antihypertensive agents or certain antipsychotics may result in the augmentation of hypotensive effects, leading to an increased drop in blood pressure. The drug's label explicitly notes a regulatory constraint regarding the treatment of Phentolamine-induced hypotension: Epinephrine (Adrenaline) is contraindicated for this purpose due to the risk of a paradoxical reduction in blood pressure. Furthermore, the concurrent use of Cardiac Glycosides may carry a risk of tachycardia and cardiac arrhythmias, necessitating caution.

Timing-Based Interaction Rules

Specific administration timing is mandated before using Regitin for its diagnostic procedure. The official prescribing information requires that non-essential medications such as sedatives and analgesics must be withheld for 24 to 72 hours prior to the test to prevent interference with procedural accuracy. Other antihypertensive drugs must also be separated until blood pressure returns to the untreated hypertensive level.

Pharmacokinetic and Substance Interactions

No extensive CYP-mediated or transporter-mediated pharmacokinetic interactions are detailed in the official regulatory documents for the injectable formulation. Official data confirms that in certain localized uses, Phentolamine did not affect the plasma concentrations (AUC/Cmax) of co-administered agents like Lidocaine.

Regitin functions as an alpha-adrenergic antagonist by binding to specific receptor subtypes within the sympathetic nervous system. The drug's mechanism is defined by two key mechanistic domains that initiate distinct physiological outcomes.

Modulation of Peripheral Vascular Signaling

This domain covers Regitin's action as a non-selective antagonist at the alpha-1 adrenergic receptors located primarily on vascular smooth muscle cells. . By blocking these receptors, the drug suppresses the signaling sequence normally initiated by the body's own catecholamines, which results in the relaxation of both arterioles and veins. This results in the physiological consequence of reduced peripheral vascular resistance due to the suppression of vasoconstrictive signaling.

---

Regulation of Neurotransmitter Feedback

This domain relates to Regitin's activity as an antagonist at the presynaptic alpha-2 adrenergic receptors. These receptors typically function as a negative feedback mechanism, limiting the release of the neurotransmitter norepinephrine from sympathetic nerve terminals. Regitin's engagement with these mechanisms blocks this self-regulation, thereby allowing for increased local norepinephrine release. This downstream effect can influence other cardiovascular processes, such as the heart rate, by modifying signaling dynamics within the targeted pathways.

How to Use Regitin

Regitin (phentolamine mesylate) is administered only in a supervised clinical setting, as it is supplied as a lyophilized powder for injection and is reserved for acute medical needs. The usage is strictly governed by precise instructions covering the administration route, dosing, and required preparation steps.

Official Routes and Preparation

The approved routes are intravenous (IV) and intramuscular (IM) injection for systemic effect, or local infiltration into the skin for treating localized issues. The powder must be reconstituted immediately before use by dissolving the 5 mg vial in 1 mL of Sterile Water for Injection, as the solution is not intended for storage. For local infiltration during extravasation treatment, the reconstituted dose is further diluted with 10 mL of normal saline.

---

Standard Dosing and Use Patterns

Administration is classified as short-term, acute use, typically involving single-instance dosing for diagnosis or a brief course for stabilization during critical events. There are no long-term or maintenance regimens described.

Indication	Adult Dose	Pediatric Dose
Pheochromocytoma (Pre-operative/Intra-operative)	5 mg IV or IM	1 mg IV or IM
Diagnostic Test	5 mg IV or IM	1 mg IV (or 3 mg IM)
Dermal Necrosis/Extravasation	5 mg to 10 mg (local injection)	Dose is based on the specific patient presentation and local protocol

For pre-operative management of pheochromocytoma, the dose is administered one to two hours before the procedure and may be repeated if necessary to maintain control. For the management of dermal necrosis following pressor agent leakage, the dose must be injected into the affected area within 12 hours of detection. The administration pattern is thus entirely driven by immediate, acute necessity.

Research Evidence / Overview of Studies for Regitin

Regitin (Phentolamine mesylate) has been studied primarily in acute hospital settings for its two main approved uses. The research base reflects the acute, specific clinical situations examined in official research and regulatory reviews. Findings describe group patterns, not personal outcomes, and evidence quality varies across studies, reflecting the challenges of conducting large-scale trials for rare and acute medical events.

---

Evidence for Acute Blood Pressure Management in Pheochromocytoma Surgery

Regitin was studied for its use in patients undergoing surgery to remove a pheochromocytoma, a tumor that is associated with severe, sudden episodes of high blood pressure. Because this condition is rare, the evidence primarily comprises clinical experience documented in case reports, case series, and older regulatory reviews. Researchers focused on outcomes related to acute changes in systolic and diastolic blood pressure during the time leading up to and immediately following the surgical procedure. The evidence, though accepted by regulators for this specific acute indication, is drawn from settings with varying symptom burdens and generally involves small populations.

---

Evidence for Addressing Local Tissue Injury from IV Pressor Agents

Regitin was studied for its use in a specific emergency scenario: addressing localized tissue injury (called necrosis or sloughing) that may occur if certain powerful intravenous pressor medications leak out of the vein into the surrounding skin tissue, which is called extravasation. The available research consists largely of case reports and case series, complemented by preclinical research and regulatory documentation. Clinical reports described patterns where local administration near the extravasation site was associated with measured changes in visible signs of local vasoconstriction (such as blanching of the skin).

---

Evidence Gaps and Areas of Uncertainty

The research on Regitin highlights several areas where certainty remains low or where additional data are needed. Research suggests the sample sizes were modest in many reports, particularly those concerning the rare pheochromocytoma condition. The evidence quality varies across studies, and there is a general consensus among researchers that comparative evidence is lacking against modern treatments across all indications. The long-term effects are not fully established, as the follow-up durations were limited.

Key Studies & References

1. Phentolamine Mesylate for Injection USP, 5mg - Official DailyMed Label
2. Multidisciplinary perioperative management of pediatric pheochromocytoma/paraganglioma: a retrospective cohort study with long-term outcomes (Includes phentolamine use)

Common questions about Regitin (FAQ)

---

Q: What should I do if I miss a dose of Regitin?

According to official product information, Regitin is only administered in a supervised clinical setting for acute (immediate) medical needs. It is not intended for patient self-administration or for long-term regimens. Due to its function for acute needs and administration in a supervised setting, the concept of a missed dose is not applicable as described in the official labeling.

---

Q: How long will I have to take Regitin?

Regulatory documents indicate its intended use is short-term and acute, typically involving single doses for diagnostic procedures or brief courses for stabilization during critical events. The medication is not prescribed for long-term or maintenance therapy, as no such regimens are described in the official labeling.

---

Q: How does Regitin actually lower blood pressure?

Regitin is an alpha-adrenergic antagonist, which means it blocks specific nerve receptors. By blocking the alpha-1 receptors on the walls of blood vessels, the drug causes them to relax, a process called vasodilation. This relaxation reduces the resistance to blood flow in the vessels, which is the pharmacological action linked to a reduction in blood pressure.

---

Q: What are the most serious side effects of Regitin?

Official safety documents mention that serious adverse reactions have been documented following injection, typically linked to marked hypotensive episodes (low blood pressure). These serious effects include Myocardial Infarction (heart attack), Cerebrovascular Spasm, and Cerebrovascular Occlusion (stroke).

---

Q: Can Regitin be taken orally?

No. Official labeling states that Regitin is supplied exclusively as a sterile, lyophilized powder that must be reconstituted (mixed) into a solution for injection. It is formulated exclusively for parenteral administration (by injection), and the official product labeling does not describe an oral route of use.

---

Q: How quickly does Regitin start to work after injection?

Regitin is formulated for injection, a route designed to achieve rapid systemic availability in acute medical situations. While specific onset-of-action times are limited in regulatory pharmacokinetic data, the injectable dosage form is characteristic of a medication intended for rapid action.

---

Q: Will Regitin make me feel sleepy?

The official documentation lists common central nervous system effects such as dizziness and headache among the adverse reactions. However, somnolence (sleepiness) is not specifically listed in the current regulatory profile. This information comes directly from the official product labeling.

How to Store and Dispose of Regitin (Phentolamine Mesylate)

The official labeling specifies distinct requirements for the unreconstituted powder and the prepared solution to maintain stability and ensure responsible handling.

---

Storage Requirements

The unreconstituted powder must be stored in a well-closed, light-resistant container at Controlled Room Temperature (CRT), defined as 20 C to 25 C. It must be protected from light, heat, moisture, and freezing.

Crucially, the solution prepared for injection must be used immediately after reconstitution and must not be stored for later use.

All medicine must be stored in a location that is out of the reach and sight of children.

Disposal Instructions

Disposal of unused or expired Regitin should follow official guidelines. Healthcare professionals should be consulted regarding proper disposal. The product must not be flushed down the sink or toilet. If disposing of the container, all identifying information on the label must be scratched out.